Antidepressants for neuro-regeneration: From depression to Alzheimer's disease

Archives of Pharmacal Research

Volumn 36, Issue 11, 2013, Pages 1279-1290

  Kim, Hyun Jung ^a   Kim, Woosuk ^a   Kong, Sun Young ^a  

^a Chung Ang University   (South Korea)

Author keywords

Alzheimer's disease; Antidepressants; Brain derived neurotrophic factor; Depression; Neurogenesis

Indexed keywords

AGOMELATINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPRONIAZID; ISOCARBOXAZID; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SERTRALINE; TESOFENSINE; TIANEPTINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; BRAIN DEPTH STIMULATION; CEREBROVASCULAR ACCIDENT; CINGULATE GYRUS; COMORBIDITY; DEGENERATIVE DISEASE; DENDRITE; DEPRESSION; EMOTIONALITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; REVIEW; SYNAPSE; TREATMENT RESISTANT DEPRESSION;

ALZHEIMER DISEASE; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; HIPPOCAMPUS; HUMANS; MODELS, NEUROLOGICAL; NEUROGENESIS;

EID: 84888101611     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0238-8     Document Type: Review

References (138)

1. Allain, H.; S. Schuck, and N. Mauduit. 2000. Depression in Parkinson's disease. British Medical Journal 320: 1287-1288.
2. Altman, J.; and G.D. Das. 1965. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. The Journal of Comparative Neurology 124: 319-335.
3. Anacker, C.; P.A. Zunszain, A. Cattaneo, L.A. Carvalho, M.J. Garabedian, S. Thuret, J. Price, and C.M. Pariante. 2011. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Molecular Psychiatry 16: 738-750.
4. Anand, P.; and B. Singh. 2013. A review on cholinesterase inhibitors for Alzheimer's disease. Archives of Pharmacal Research 36: 375-399.
5. Antonini, A.; S. Tesei, A. Zecchinelli, P. Barone, D. De Gaspari, M. Canesi, G. Sacilotto, N. Meucci, C. Mariani, and G. Pezzoli. 2006. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. Movement Disorders 21: 1119-1122.
6. Arlt, S.; C. Demiralay, B. Tharun, O. Geisel, N. Storm, M. Eichenlaub, J.T. Lehmbeck, K. Wiedemann, B. Leuenberger, and H. Jahn. 2013. Genetic risk factors for depression in Alzheimer's disease patients. Current Alzheimer Research 10: 72-81.
7. Ballard, C.; S. Gauthier, A. Corbett, C. Brayne, D. Aarsland, and E. Jones. 2011. Alzheimer's disease. Lancet 377: 1019-1031.
8. Banasr, M.; A. Soumier, M. Hery, E. Mocaer, and A. Daszuta. 2006. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biological Psychiatry 59: 1087-1096.
9. Barak, Y.; E. Ur, and A. Achiron. 1999. Moclobemide treatment in multiple sclerosis patients with comorbid depression: An open-label safety trial. The Journal of neuropsychiatry and clinical neurosciences 11: 271-273.
10. Benedetti, F.; E. Campori, C. Colombo, and E. Smeraldi. 2004. Fluvoxamine treatment of major depression associated with multiple sclerosis. The Journal of neuropsychiatry and clinical neurosciences 16: 364-366.
11. Bianchi, P.; E. Ciani, S. Guidi, S. Trazzi, D. Felice, G. Grossi, M. Fernandez, A. Giuliani, L. Calza, and R. Bartesaghi. 2010. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for down syndrome. The Journal of Neuroscience 30: 8769-8779.
12. Boldrini, M.; M.D. Underwood, R. Hen, G.B. Rosoklija, A.J. Dwork, J. John Mann, and V. Arango. 2009. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 34: 2376-2389.
13. Bonelli, R.M. 2003. Mirtazapine in suicidal Huntington's disease. The Annals of Pharmacotherapy 37: 452.
14. Braak, H.; E. Braak, and J. Bohl. 1993. Staging of Alzheimer-related cortical destruction. European Neurology 33: 403-408.
15. Brady, R.; and J. Weinman. 2013. Adherence to cholinesterase inhibitors in Alzheimer's disease: A review. Dementia and Geriatric Cognitive Disorders 35: 351-363.
16. Cameron, H.A.; C.S. Woolley, B.S. Mcewen, and E. Gould. 1993. Differentiation of newly born neurons and glia in the dentate gyrus of the adult rat. Neuroscience 56: 337-344.
17. Chadwick, W.; N. Mitchell, J. Caroll, Y. Zhou, S.S. Park, L. Wang, K.G. Becker, Y. Zhang, E. Lehrmann, W.H. Wood 3rd, B. Martin, and S. Maudsley. 2011. Amitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 6: e21660.
18. Chao, M.V. 2003. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nature Reviews Neuroscience 4: 299-309.
19. Chen, F.; T.M. Madsen, G. Wegener, and J.R. Nyengaard. 2010. Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. Hippocampus 20: 1376-1384.
20. Chen, Z.Y.; D. Jing, K.G. Bath, A. Ieraci, T. Khan, C.J. Siao, D.G. Herrera, M. Toth, C. Yang, B.S. Mcewen, B.L. Hempstead, and F.S. Lee. 2006. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 314: 140-143.
21. Cirrito, J.R.; B.M. Disabato, J.L. Restivo, D.K. Verges, W.D. Goebel, A. Sathyan, D. Hayreh, G. D'angelo, T. Benzinger, H. Yoon, J. Kim, J.C. Morris, M.A. Mintun, and Y.I. Sheline. 2011. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America 108: 14968-14973.
22. Colman, I.; Y. Garad, Y. Zeng, K. Naicker, M. Weeks, S.B. Patten, P.B. Jones, A.H. Thompson, and T.C. Wild. 2013. Stress and development of depression and heavy drinking in adulthood: Moderating effects of childhood trauma. Social Psychiatry and Psychiatric Epidemiology 48: 265-274.
23. Coppell, A.L.; Q. Pei, and T.S. Zetterstrom. 2003. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 44: 903-910.
24. Czeh, B.; T. Michaelis, T. Watanabe, J. Frahm, G. De Biurrun, M. Van Kampen, A. Bartolomucci, and E. Fuchs. 2001. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proceedings of the National Academy of Sciences of the United States of America 98: 12796-12801.
25. Dagyte, G.; I. Crescente, F. Postema, L. Seguin, C. Gabriel, E. Mocaer, J.A. Boer, and J.M. Koolhaas. 2011. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behavioural Brain Research 218: 121-128.
26. Dagyte, G.; A. Trentani, F. Postema, P.G. Luiten, J.A. Den Boer, C. Gabriel, E. Mocaer, P. Meerlo, and E.A. Van Der Zee. 2010. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neuroscience and Therapeutics 16: 195-207.
27. David, D.J.; B.A. Samuels, Q. Rainer, J.W. Wang, D. Marsteller, I. Mendez, M. Drew, D.A. Craig, B.P. Guiard, J.P. Guilloux, R.P. Artymyshyn, A.M. Gardier, C. Gerald, I.A. Antonijevic, E.D. Leonardo, and R. Hen. 2009. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62: 479-493.
28. Dias, B.G.; S.B. Banerjee, R.S. Duman, and V.A. Vaidya. 2003. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 45: 553-563.
29. Drevets, W.C. 2001. Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Current Opinion in Neurobiology 11: 240-249.
30. Duan, W.; Q. Peng, N. Masuda, E. Ford, E. Tryggestad, B. Ladenheim, M. Zhao, J.L. Cadet, J. Wong, and C.A. Ross. 2008. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiology of Disease 30: 312-322.
31. Dwivedi, Y. 2013. Involvement of brain-derived neurotrophic factor in late-life depression. The American Journal of Geriatric Psychiatry 21: 433-449.
32. Egan, M.F.; M. Kojima, J.H. Callicott, T.E. Goldberg, B.S. Kolachana, A. Bertolino, E. Zaitsev, B. Gold, D. Goldman, M. Dean, B. Lu, and D.R. Weinberger. 2003. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269.
33. Feinstein, A. 2011. Multiple sclerosis and depression. Multiple Sclerosis 17: 1276-1281.
34. Finkel, S.I.; J.E. Mintzer, M. Dysken, K.R. Krishnan, T. Burt, and T. Mcrae. 2004. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. International Journal of Geriatric Psychiatry 19: 9-18.
35. First, M.; I. Gil-Ad, M. Taler, I. Tarasenko, N. Novak, and A. Weizman. 2013. The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress. Journal of Molecular Neuroscience 50: 88-97.
36. Gorman, J.M. 1996. Comorbid depression and anxiety spectrum disorders. Depression and Anxiety 4: 160-168.
37. Hampel, H.; D. Prvulovic, S. Teipel, F. Jessen, C. Luckhaus, L. Frolich, M.W. Riepe, R. Dodel, T. Leyhe, L. Bertram, W. Hoffmann, F. Faltraco, and German Task Force on Alzheimer's, Disease. 2011. The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology 95: 718-728.
38. Han, X.; J. Tong, J. Zhang, A. Farahvar, E. Wang, J. Yang, U. Samadani, D.H. Smith, and J.H. Huang. 2011. Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice. Journal of Neurotrauma 28: 995-1007.
39. Harrison, P.J. 2002. The neuropathology of primary mood disorder. Brain: A Journal of Neurology 125: 1428-1449.
40. Hitoshi, S.; N. Maruta, M. Higashi, A. Kumar, N. Kato, and K. Ikenaka. 2007. Antidepressant drugs reverse the loss of adult neural stem cells following chronic stress. Journal of Neuroscience Research 85: 3574-3585.
41. Hochgrafe, K.; A. Sydow, and E.M. Mandelkow. 2013. Regulatable transgenic mouse models of Alzheimer disease: Onset, reversibility and spreading of tau pathology. The FEBS Journal. doi: 10.1111/febs.12250.
42. Holl, A.K.; L. Wilkinson, A. Painold, E.M. Holl, and R.M. Bonelli. 2010. Combating depression in Huntington's disease: Effective antidepressive treatment with venlafaxine XR. International Clinical Psychopharmacology 25: 46-50.
43. Hu, P.; C. Oomen, A.M. Van Dam, J. Wester, J.N. Zhou, M. Joels, and P.J. Lucassen. 2012. A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. PLoS One 7: e46224.
44. Huang, G.J.; and J. Herbert. 2006. Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone. Biological Psychiatry 59: 619-624.
45. Huang, T.L.; C.T. Lee, and Y.L. Liu. 2008. Serum brain-derived neurotrophic factor levels in patients with major depression: Effects of antidepressants. Journal of Psychiatric Research 42: 521-525.
46. Huang, Y.Y.; C.H. Peng, Y.P. Yang, C.C. Wu, W.M. Hsu, H.J. Wang, K.H. Chan, Y.P. Chou, S.J. Chen, and Y.L. Chang. 2007. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. Journal of Pharmacological Sciences 104: 61-72.
47. Hurley, L.L.; and Y. Tizabi. 2013. Neuroinflammation, neurodegeneration, and depression. Neurotoxicity Research 23: 131-144.
48. Jaako-Movits, K.; T. Zharkovsky, M. Pedersen, and A. Zharkovsky. 2006. Decreased hippocampal neurogenesis following olfactory bulbectomy is reversed by repeated citalopram administration. Cellular and Molecular Neurobiology 26: 1559-1570.
49. Jaako, K.; T. Zharkovsky, and A. Zharkovsky. 2009. Effects of repeated citalopram treatment on kainic acid-induced neurogenesis in adult mouse hippocampus. Brain Research 1288: 18-28.
50. Jayatissa, M.N.; C. Bisgaard, A. Tingstrom, M. Papp, and O. Wiborg. 2006. Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression. Neuropsychopharmacology 31: 2395-2404.
51. Keilhoff, G.; A. Becker, G. Grecksch, H.G. Bernstein, and G. Wolf. 2006. Cell proliferation is influenced by bulbectomy and normalized by imipramine treatment in a region-specific manner. Neuropsychopharmacology 31: 1165-1176.
52. Kim, H.J. 2011. Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons. Biochimica et Biophysica Acta 1812: 1-11.
53. Kim, H.J.; J.J. Hwang, M.M. Behrens, B.J. Snider, D.W. Choi, and J.Y. Koh. 2003. TrkB mediates BDNF-induced potentiation of neuronal necrosis in cortical culture. Neurobiology of disease 14: 110-119.
54. Kim, H.J.; and C.Y. Jin. 2012. Stem cells in drug screening for neurodegenerative disease. The Korean Journal of Physiology and Pharmacology 16: 1-9.
55. Kim, H.J.; and M.G. Rosenfeld. 2010. Epigenetic control of stem cell fate to neurons and glia. Archieves of Pharmacal Research 33: 1467-1473.
56. Kitamura, Y.; M. Doi, K. Kuwatsuka, Y. Onoue, I. Miyazaki, K. Shinomiya, T. Koyama, T. Sendo, H. Kawasaki, M. Asanuma, and Y. Gomita. 2011. Chronic treatment with imipramine and lithium increases cell proliferation in the hippocampus in adrenocorticotropic hormone-treated rats. Biological and Pharmaceutical Bulletin 34: 77-81.
57. Koh, J.Y.; B.J. Gwag, D. Lobner, and D.W. Choi. 1995. Potentiated necrosis of cultured cortical neurons by neurotrophins. Science 268: 573-575.
58. Kohl, Z.; B. Winner, K. Ubhi, E. Rockenstein, M. Mante, M. Munch, C. Barlow, T. Carter, E. Masliah, and J. Winkler. 2012. Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model. The European Journal of Neuroscience 35: 10-19.
59. Ladea, M.; and M. Bran. 2013. Brain derived neurotrophic factor (BDNF) levels in depressed women treated with open-label escitalopram. Psychiatria Danubina 25: 128-132.
60. Larsen, M.H.; H. Rosenbrock, F. Sams-Dodd, and J.D. Mikkelsen. 2007. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. European Journal of Pharmacology 555: 115-121.
61. Lau, W.M.; G. Qiu, D.M. Helmeste, T.M. Lee, S.W. Tang, K.F. So, and S.W. Tang. 2007. Corticosteroid decreases subventricular zone cell proliferation, which could be reversed by paroxetine. Restorative Neurology and Neuroscience 25: 17-23.
62. Lee, B.H.; and Y.K. Kim. 2009. Reduced platelet BDNF level in patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 33: 849-853.
63. Lee, H.B.; and C.G. Lyketsos. 2003. Depression in Alzheimer's disease: Heterogeneity and related issues. Biological Psychiatry 54: 353-362.
64. Lee, R.; P. Kermani, K.K. Teng, and B.L. Hempstead. 2001. Regulation of cell survival by secreted proneurotrophins. Science 294: 1945-1948.
65. Lemke, M.R. 2002. Effect of reboxetine on depression in Parkinson's disease patients. The Journal of Clinical Psychiatry 63: 300-304.
66. Lesemann, A.; C. Reinel, P. Huhnchen, M. Pilhatsch, R. Hellweg, P. Klaissle, C. Winter, and B. Steiner. 2012. MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. Brain Research 1457: 51-69.
67. Lesne, S.E.; M.A. Sherman, M. Grant, M. Kuskowski, J.A. Schneider, D.A. Bennett, and K.H. Ashe. 2013. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain: A Journal of Neurology 136: 1383-1398.
68. Levison, S.W.; and J.E. Goldman. 1993. Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain. Neuron 10: 201-212.
69. Li, W.L.; H.H. Cai, B. Wang, L. Chen, Q.G. Zhou, C.X. Luo, N. Liu, X.S. Ding, and D.Y. Zhu. 2009. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. Journal of Neuroscience Research 87: 112-122.
70. Li, Y.; B.W. Luikart, S. Birnbaum, J. Chen, C.H. Kwon, S.G. Kernie, R. Bassel-Duby, and L.F. Parada. 2008. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 59: 399-412.
71. Lipsey, J.R.; R.G. Robinson, G.D. Pearlson, K. Rao, and T.R. Price. 1984. Nortriptyline treatment of post-stroke depression: A double-blind study. Lancet 1: 297-300.
72. Liu, Q.; J. Yu, Q.L. Mao-Ying, W.L. Mi, B. Li, Y.Q. Wang, J. Wang, and G.C. Wu. 2008. Repeated clomipramine treatment reversed the inhibition of cell proliferation in adult hippocampus induced by chronic unpredictable stress. The Pharmacogenomics Journal 8: 375-383.
73. Lois, C.; and A. Alvarez-Buylla. 1994. Long-distance neuronal migration in the adult mammalian brain. Science 264: 1145-1148.
74. Lopez-Juarez, A.; J. Howard, K. Ullom, L. Howard, A. Grande, A. Pardo, R. Waclaw, Y.Y. Sun, D. Yang, C.Y. Kuan, K. Campbell, and M. Nakafuku. 2013. Gsx2 controls region-specific activation of neural stem cells and injury-induced neurogenesis in the adult subventricular zone. Genes and Development 27: 1272-1287.
75. Lyketsos, C.G.; L. Delcampo, M. Steinberg, Q. Miles, C.D. Steele, C. Munro, A.S. Baker, J.M. Sheppard, C. Frangakis, J. Brandt, and P.V. Rabins. 2003. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Archives of General Psychiatry 60: 737-746.
76. Lyketsos, C.G.; J.M. Sheppard, C.D. Steele, S. Kopunek, M. Steinberg, A.S. Baker, J. Brandt, and P.V. Rabins. 2000. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study. The American Journal of Psychiatry 157: 1686-1689.
77. Lyketsos, C.G.; C. Steele, L. Baker, E. Galik, S. Kopunek, M. Steinberg, and A. Warren. 1997. Major and minor depression in Alzheimer's disease: Prevalence and impact. The Journal of Neuropsychiatry and Clinical Neurosciences 9: 556-561.
78. Lyons, L.; M. Elbeltagy, J. Umka, R. Markwick, C. Startin, G. Bennett, and P. Wigmore. 2011. Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology (Berl) 215: 105-115.
79. Malberg, J.E.; A.J. Eisch, E.J. Nestler, and R.S. Duman. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. Journal of Neuroscience 20: 9104-9110.
80. Marcussen, A.B.; P. Flagstad, P.E. Kristjansen, F.F. Johansen, and U. Englund. 2008. Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurologica Scandinavica 117: 94-100.
81. Marlatt, M.W.; P.J. Lucassen, and H. Van Praag. 2010. Comparison of neurogenic effects of fluoxetine, duloxetine and running in mice. Brain Research 1341: 93-99.
82. Mayberg, H.S.; M. Liotti, S.K. Brannan, S. Mcginnis, R.K. Mahurin, P.A. Jerabek, J.A. Silva, J.L. Tekell, C.C. Martin, J.L. Lancaster, and P.T. Fox. 1999. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. The American Journal of Psychiatry 156: 675-682.
83. Mayberg, H.S.; A.M. Lozano, V. Voon, H.E. Mcneely, D. Seminowicz, C. Hamani, J.M. Schwalb, and S.H. Kennedy. 2005. Deep brain stimulation for treatment-resistant depression. Neuron 45: 651-660.
84. Mcewen, B.S. 1999. Stress and hippocampal plasticity. Annual Review of Neuroscience 22: 105-122.
85. Menke, A.; T. Klengel, J. Rubel, T. Bruckl, H. Pfister, S. Lucae, M. Uhr, F. Holsboer, and E.B. Binder. 2013. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes, Brain, and Behavior 12: 289-296.
86. Menza, M.; R.D. Dobkin, H. Marin, M.H. Mark, M. Gara, S. Buyske, K. Bienfait, and A. Dicke. 2009. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72: 886-892.
87. Milad, M.R.; G.J. Quirk, R.K. Pitman, S.P. Orr, B. Fischl, and S.L. Rauch. 2007. A role for the human dorsal anterior cingulate cortex in fear expression. Biological Psychiatry 62: 1191-1194.
88. Mohr, D.C.; A.C. Boudewyn, D.E. Goodkin, A. Bostrom, and L. Epstein. 2001. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. Journal of Consulting and Clinical Psychology 69: 942-949.
89. Mostany, R.; E.M. Valdizan, and A. Pazos. 2008. A role for nuclear beta-catenin in SNRI antidepressant-induced hippocampal cell proliferation. Neuropharmacology 55: 18-26.
90. Mowla, A.; M. Mosavinasab, H. Haghshenas, and A. Borhani Haghighi. 2007. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. Journal of Clinical Psychopharmacology 27: 484-487.
91. Nasrallah, H.A.; T. Hopkins, and S.K. Pixley. 2010. Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats. Brain Research 1354: 23-29.
92. Neto, F.L.; G. Borges, S. Torres-Sanchez, J.A. Mico, and E. Berrocoso. 2011. Neurotrophins role in depression neurobiology: A review of basic and clinical evidence. Current Neuropharmacology 9: 530-552.
93. Nuti, A.; R. Ceravolo, A. Piccinni, G. Dell'agnello, G. Bellini, G. Gambaccini, C. Rossi, C. Logi, L. Dell'osso, and U. Bonuccelli. 2004. Psychiatric comorbidity in a population of Parkinson's disease patients. European Journal of Neurology 11: 315-320.
94. Paolucci, S. 2008. Epidemiology and treatment of post-stroke depression. Neuropsychiatric Disease and Treatment 4: 145-154.
95. Pechnick, R.N.; S. Zonis, K. Wawrowsky, R. Cosgayon, C. Farrokhi, L. Lacayo, and V. Chesnokova. 2011. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One 6: e27290.
96. Peng, C.H.; S.H. Chiou, S.J. Chen, Y.C. Chou, H.H. Ku, C.K. Cheng, C.J. Yen, T.H. Tsai, Y.L. Chang, and C.L. Kao. 2008a. Neuroprotection by imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. European Neuropsychopharmacology 18: 128-140.
97. Peng, Q.; N. Masuda, M. Jiang, Q. Li, M. Zhao, C.A. Ross, and W. Duan. 2008b. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Experimental Neurology 210: 154-163.
98. Peng, Z.W.; Y.Y. Xue, H.N. Wang, H.H. Wang, F. Xue, F. Kuang, B.R. Wang, Y.C. Chen, L.Y. Zhang, and Q.R. Tan. 2012. Sertraline promotes hippocampus-derived neural stem cells differentiating into neurons but not glia and attenuates LPS-induced cellular damage. Progress in Neuro-Psychopharmacology and Biological Psychiatry 36: 183-188.
99. Perera, T.D.; A.J. Dwork, K.A. Keegan, L. Thirumangalakudi, C.M. Lipira, N. Joyce, C. Lange, J.D. Higley, G. Rosoklija, R. Hen, H.A. Sackeim, and J.D. Coplan. 2011. Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One 6: e17600.
100. Petracca, G.; A. Teson, E. Chemerinski, R. Leiguarda, and S.E. Starkstein. 1996. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences 8: 270-275.
101. Price, A.; L. Rayner, E. Okon-Rocha, A. Evans, K. Valsraj, I.J. Higginson, and M. Hotopf. 2011. Antidepressants for the treatment of depression in neurological disorders: A systematic review and meta-analysis of randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry 82: 914-923.
102. Querfurth, H.W.; and F.M. Laferla. 2010. Alzheimer's disease. The New England Journal of Medicine 362: 329-344.
103. Raffaele, R.; L. Rampello, I. Vecchio, C. Tornali, and M. Malaguarnera. 1996. Trazodone therapy of the post-stroke depression. Archives of Gerontology and Geriatrics 22(Suppl 1): 217-220.
104. Rampello, L.; A. Alvano, S. Chiechio, R. Raffaele, I. Vecchio, and M. Malaguarnera. 2005. An evaluation of efficacy and safety of reboxetine in elderly patients affected by "retarded" post-stroke depression. A random, placebo-controlled study. Archives of Gerontology and Geriatrics 40: 275-285.
105. Ranoux, D. 2000. Depression and Parkinson disease. L'Encephale 26(Spec No 3): 22-26.
106. Rao, V.; J.R. Spiro, P.B. Rosenberg, H.B. Lee, A. Rosenblatt, and C.G. Lyketsos. 2006. An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD). International Journal of Geriatric Psychiatry 21: 273-274.
107. Raskind, M.A. 2008. Diagnosis and treatment of depression comorbid with neurologic disorders. The American Journal of Medicine 121: S28-S37.
108. Rayen, I.; D.L. Van Den Hove, J. Prickaerts, H.W. Steinbusch, and J.L. Pawluski. 2011. Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. PLoS One 6: e24003.
109. Reifler, B.V.; L. Teri, M. Raskind, R. Veith, R. Barnes, E. White, and P. Mclean. 1989. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. The American Journal of Psychiatry 146: 45-49.
110. Ressler, K.J.; and H.S. Mayberg. 2007. Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nature Neuroscience 10: 1116-1124.
111. Richard, I.H.; M.P. Mcdermott, R. Kurlan, J.M. Lyness, P.G. Como, N. Pearson, S.A. Factor, J. Juncos, C. Serrano Ramos, M. Brodsky, C. Manning, L. Marsh, L. Shulman, H.H. Fernandez, K.J. Black, M. Panisset, C.W. Christine, W. Jiang, C. Singer, S. Horn, R. Pfeiffer, D. Rottenberg, J. Slevin, L. Elmer, D. Press, H.C. Hyson, W. Mcdonald, and S.-P. Group. 2012. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78: 1229-1236.
112. Ristevska-Dimitrovska, G.; R. Shishkov, V.P. Gerazova, V. Vujovik, B. Stefanovski, A. Novotni, P. Marinov, and I. Filov. 2013. Different serum BDNF levels in depression: Results from BDNF studies in FYR Macedonia and Bulgaria. Psychiatria Danubina 25: 123-127.
113. Robinson, R.G.; S.K. Schultz, C. Castillo, T. Kopel, J.T. Kosier, R.M. Newman, K. Curdue, G. Petracca, and S.E. Starkstein. 2000. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: A placebo-controlled, double-blind study. The American Journal of Psychiatry 157: 351-359.
114. Roos, R.A. 2010. Huntington's disease: A clinical review. Orphanet Journal of Rare Diseases 5: 40.
115. Rossi, C.; A. Angelucci, L. Costantin, C. Braschi, M. Mazzantini, F. Babbini, M.E. Fabbri, L. Tessarollo, L. Maffei, N. Berardi, and M. Caleo. 2006. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. The European Journal of Neuroscience 24: 1850-1856.
116. Russo-Neustadt, A.A.; H. Alejandre, C. Garcia, A.S. Ivy, and M.J. Chen. 2004. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 29: 2189-2199.
117. Sairanen, M.; G. Lucas, P. Ernfors, M. Castren, and E. Castren. 2005. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. The Journal of Neuroscience 25: 1089-1094.
118. Sandhya, V.K.; Raju, R.; Verma, R.; Advani, J.; Sharma, R.; Radhakrishnan, A.; Nanjappa, V.; Narayana, J.; Somani, B. L.; Mukherjee, K. K.; Pandey, A.; Christopher, R.; and T.S. Prasad. 2013. A network map of BDNF/TRKB and BDNF/p75NTR signaling system. Journal of Cell Communication and Signaling. doi: 10.1007/s12079-013-0200-z.
119. Savitz, J.B.; and W.C. Drevets. 2013. Neuroreceptor imaging in depression. Neurobiology of Disease 52: 49-65.
120. Scharfman, H.; J. Goodman, A. Macleod, S. Phani, C. Antonelli, and S. Croll. 2005. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Experimental Neurology 192: 348-356.
121. Schiavon, A.P.; H. Milani, C.V. Romanini, M.L. Foresti, O.W. Castro, N. Garcia-Cairasco, and R.M. De Oliveira. 2010. Imipramine enhances cell proliferation and decreases neurodegeneration in the hippocampus after transient global cerebral ischemia in rats. Neuroscience Letters 470: 43-48.
122. Selkoe, D.J. 2011. Alzheimer's disease. Cold Spring Harbor perspectives in biology. doi: 10.1101/cshperspect.a004457.
123. Shapero, B.G.; S.K. Black, R.T. Liu, J. Klugman, R.E. Bender, L.Y. Abramson, and L.B. Alloy. 2013. Stressful life events and depression symptoms: The effect of childhood emotional abuse on stress reactivity. Journal of clinical psychology. doi: 10.1002/jclp.22011.
124. Shirayama, Y.; A.C. Chen, S. Nakagawa, D.S. Russell, and R.S. Duman. 2002. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. The Journal of Neuroscience 22: 3251-3261.
125. Siuciak, J.A.; C. Boylan, M. Fritsche, C.A. Altar, and R.M. Lindsay. 1996. BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. Brain Research 710: 11-20.
126. Soumier, A.; M. Banasr, S. Lortet, F. Masmejean, N. Bernard, L. Kerkerian-Le-Goff, C. Gabriel, M.J. Millan, E. Mocaer, and A. Daszuta. 2009. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 34: 2390-2403.
127. Sui, Y.; Z. Zhang, Y. Guo, Y. Sun, X. Zhang, C. Xie, Y. Li, and G. Xi. 2009. The function of Notch1 signaling was increased in parallel with neurogenesis in rat hippocampus after chronic fluoxetine administration. Biological and Pharmaceutical Bulletin 32: 1776-1782.
128. Surget, A.; M. Saxe, S. Leman, Y. Ibarguen-Vargas, S. Chalon, G. Griebel, R. Hen, and C. Belzung. 2008. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biological Psychiatry 64: 293-301.
129. Taliaz, D.; N. Stall, D.E. Dar, and A. Zangen. 2010. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Molecular Psychiatry 15: 80-92.
130. Taragano, F.E.; C.G. Lyketsos, C.A. Mangone, R.F. Allegri, and E. Comesana-Diaz. 1997. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38: 246-252.
131. Thies, W.; L. Bleiler, and A. Alzheimer's. 2013. Alzheimer's disease facts and figures. Alzheimer's and dementia. The Journal of the Alzheimer's Association 9: 208-245.
132. Van Hoomissen, J.D.; H.O. Chambliss, P.V. Holmes, and R.K. Dishman. 2003. Effects of chronic exercise and imipramine on mRNA for BDNF after olfactory bulbectomy in rat. Brain Research 974: 228-235.
133. Vinet, J.; S. Carra, J.M. Blom, N. Brunello, N. Barden, and F. Tascedda. 2004. Chronic treatment with desipramine and fluoxetine modulate BDNF, CaMKKalpha and CaMKKbeta mRNA levels in the hippocampus of transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuropharmacology 47: 1062-1069.
134. Wang, S.H.; Z.J. Zhang, Y.J. Guo, Y.X. Sui, and Y. Sun. 2010. Notch1 signaling related hippocampal neurogenesis in adult poststroke depression rats: A valid index for an efficient combined citalopram and WAY100635 pharmacotherapy. Behavioural Pharmacology 21: 47-57.
135. Wang, Y.; M. Neumann, K. Hansen, S.M. Hong, S. Kim, L.J. Noble-Haeusslein, and J. Liu. 2011. Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury. Journal of Neurotrauma 28: 259-268.
136. Wiart, L.; H. Petit, P.A. Joseph, J.M. Mazaux, and M. Barat. 2000. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31: 1829-1832.
137. Xu, H.; Z. Chen, J. He, S. Haimanot, X. Li, L. Dyck, and X.M. Li. 2006. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 16: 551-559.
138. Yanpallewar, S.U.; K. Fernandes, S.V. Marathe, K.C. Vadodaria, D. Jhaveri, K. Rommelfanger, U. Ladiwala, S. Jha, V. Muthig, L. Hein, P. Bartlett, D. Weinshenker, and V.A. Vaidya. 2010. Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. The Journal of Neuroscience 30: 1096-1109.